Galderma stock: Citi sets CHF 185.00 target for Galderma stock

Published on 10/21/2026 at 15:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On September 21, 2026, Galderma set 19-21 percent growth. Galderma stock costs EUR 189.50 on October 21, 2026, up 0.11 percent on SIX.

Citi target and market dates

Citi set a CHF 185.00 target for Galderma on October 16, 2026.
Galderma will present eight scientific abstracts at AMWC Dubai from October 21 to October 23, 2026.
Galderma stock costs EUR 189.50 at Lang & Schwarz on October 21, 2026 at 3:10 p.m. CEST, while the SIX quote was up 0.11 percent.
The next earnings call is scheduled for October 22, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) carries a CHF 185.00 Citi price target, 5.59 percent above the SIX quote of CHF 175.20 on October 21, 2026. As Business Insider reported on October 16, 2026, Citi initiated coverage with a Buy rating and set the target at CHF 185.00. At Lang & Schwarz, the stock was trading at EUR 189.50 on October 21, 2026 at 3:10 p.m. CEST; the SIX quote was up 0.11 percent on the day.

Eight studies anchor the next event

Galderma will present eight scientific abstracts at AMWC Dubai from October 21 to October 23, 2026, covering Sculptra, Restylane and Relfydess. The company also scheduled six Meet-the-Expert sessions and a symposium on expanded body indications for Sculptra. Galderma dated the release October 21, 2026.

CHF 188.25 marks the yearly high

The SIX quote stood at CHF 175.20 on October 21, 2026 at 3:01 p.m. CEST, within a 52-week range of CHF 134.90 to CHF 188.25. The session volume was 86,284 shares, while market capitalization reached CHF 40.9 billion and the P/E ratio was 58.40.

Valuation at 58.40 times earnings

Galderma's first-half 2026 net sales rose 24.60 percent year over year at constant currency, and the company raised its full-year sales-growth guidance to 19-21 percent from 17-20 percent on September 21, 2026. Its core EBITDA margin guidance remained approximately 26 percent. Galderma also said the company joined the Swiss Market Index on that date.

S&P Global Ratings upgraded Galderma to BBB+ from BBB on September 24, 2026. The agency cited first-half growth and deleveraging, while identifying higher investment needs, tariffs and competitive pressure as risks to its assessment.

Dates investors can mark

The AMWC Dubai program runs from October 21 to October 23, 2026, and Galderma's symposium is scheduled for October 22, 2026. Yahoo Finance lists the next Galderma earnings call for October 22, 2026.

Stock stays below CHF 188.25

Galderma's SIX quote of CHF 175.20 on October 21, 2026 leaves it CHF 13.05 below the 52-week high of CHF 188.25. The euro quote was EUR 189.50 at Lang & Schwarz on October 21, 2026 at 3:10 p.m. CEST, while the SIX stock was up 0.11 percent on the day.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.